Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,652JPY
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
¥2,652
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,365,514
52-wk High
¥2,800
52-wk Low
¥2,284

Chart for

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.83
Market Cap(Mil.): ¥1,898,378.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.61

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

BRIEF- Daiichi Sankyo to repurchase shares for up to 50 bln yen

* Says it plans to buy back up to 28 million shares, representing 4.2 percent of outstanding, for up to 50 billion yen, during period from Nov. 1 to March 23, 2018

Oct 31 2017

BRIEF-Daiichi Sankyo to buy back up to 50 bln yen of stock

* Says it will buy back up to 50 billion yen ($442 million) of stock through March 23 Further company coverage: ($1 = 113.1500 yen) (Reporting By Chris Gallagher)

Oct 31 2017

BRIEF-Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​

* ‍Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​ Source text for Eikon: Further company coverage:

Oct 31 2017

BRIEF-Inovalon enters into agreement with Daiichi Sankyo Inc

* Inovalon announces agreement with daiichi sankyo, inc. To support outcomes-based contracting

Sep 21 2017

Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca

TOKYO Japanese drugmaker Daiichi Sankyo denied on Thursday it received a takeover bid last year from Britain's AstraZeneca, following speculation that sent its share price soaring as much as 13 percent and triggered a trade suspension.

Aug 31 2017

UPDATE 3-Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca

* Speculation of takeover interest triggered share suspension

Aug 31 2017

Daiichi Sankyo denies receiving takeover bid from AstraZeneca

LONDON Japan's Daiichi Sankyo denied on Thursday it had received a takeover bid last year from British drugmaker AstraZeneca, as reported earlier by the online version of Nikkei Business.

Aug 31 2017

BRIEF-Daiichi Sankyo terminates product agreement with Charleston Laboratories

* Daiichi Sankyo terminates development and commercialization agreement with Charleston Laboratories regarding hydrocodone products in the U.S., including CL-108

Aug 31 2017

BRIEF-Daiichi Sankyo late-stage trial positive on diabetic pain drug

* Daiichi Sankyo announces positive top-line results from Phase 3 clinical trial evaluating mirogabalin in diabetic peripheral neuropathic pain

Aug 31 2017

UPDATE 1-UK Stocks-Factors to watch on Aug 31

Aug 31 Britain's FTSE 100 index is seen opening up 14 points on Thursday, according to financial bookmakers, with futures up 0.2 percent ahead of the cash market open.

Aug 31 2017

Earnings vs. Estimates